Building Trust and Fostering Collaborations Key to Startup Formation
November 29, 2023
One of the hardest points on the translational road “from bench to bedside” can be the point where you have to turn over your discovery to a company you’ve founded—a company whose subsequent direction you won’t fully control.
New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer
November 3, 2023
Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer. The clinical trial showed that the “radiopharmaceutical” was well tolerated and demonstrated promising antitumor activity, according to a new study published on Nov. 2 in the Journal of Clinical Oncology.
Dr. Chenxu Zhu Receives NIH Director’s New Innovator Award
October 2, 2023
Dr. Chenxu Zhu, an assistant professor of physiology and biophysics at Weill Cornell Medicine and a core faculty member of the New York Genome Center, has been awarded the National Institutes of Health Director’s New Innovator Award to fund an ambitious project to develop single-cell sequencing tools, known collectively as “multi-omics,” that will help track age-related changes in gene regulation programs, as well as cell decay, in brain cells from preclinical models.
Intercampus Symposium Brings Together Cornell Researchers Studying Metabolic Health
October 1, 2023
Diabetes, obesity, and metabolic diseases are complex health problems and important threats to human health. Ensuring optimal metabolic health requires multidisciplinary solutions. On Sept. 11 and 12, a cross-campus symposium brought together nearly 100 Cornell researchers from the Ithaca Campus and the Weill Cornell Medicine Campus in New York City to catalyze the kind of interdisciplinary collaborations necessary to address this growing health challenge.
NIH Center Grant Bolsters Male Contraceptive Research
September 21, 2023
Weill Cornell Medicine has received a three-year, nearly $6 million grant to lead one of three national contraceptive research centers. The grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health, will fund the Weill Cornell Medicine Contraception Development Research Center. Led by Drs. Jochen Buck and Lonny Levin, both professors of pharmacology at Weill Cornell Medicine, the center will focus on developing an on-demand male contraceptive.
Budding Entrepreneurial Success at Weill Cornell Medicine-Qatar
September 18, 2023
Dr. Hani Najafi, an assistant professor of cell and developmental biology, was the first WCM-Q participant in the $100K Biomedical Business Plan Challenge Pitch Day competition hosted by the BioVenture eLab. Enterprise Innovation asked him to share his latest study that can lead to potential therapies for cardiometabolic diseases and obesity.
Entrepreneurship and the Power of Story Telling
September 12, 2023
An Accelerating BioVenture Innovation (ABI) student asked Dr. Erandi De Silva, the guest speaker of the Fall 2023 cohort kickoff event hosted on Aug. 29 in a packed Uris Auditorium, how she was able to convince venture capitalists with an idea of gene therapy development and operationalization on paper.
Potential Neuropathic Pain Treatment Shows Promise in Preclinical Tests
August 9, 2023
A non-opioid designer molecule for treating chronic neuropathic pain by calming hyperactive pain-sensing neurons in the peripheral nervous system has had promising results in a preclinical study conducted by researchers at Weill Cornell Medicine and the Burke Neurological Institute.
Stroke Detection and Education App Shows Encouraging Results in Pilot Program
July 24, 2023
In 2019, Dr. Evan Noch, an assistant professor of neurology at Weill Cornell Medicine, led a team of graduate students to win the “Most Impactful Hack” award at the third annual NYC Health Hackathon. After completing a pilot program at the Burke Neurological Institute, Destroke is set to refine its prototype, expand usership and conduct randomized trials with larger patient samples, including one at Weill Cornell Medicine.